37
1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School

1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

Embed Size (px)

Citation preview

Page 1: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

1

ADVANCED HEART FAILURERECOGNIZING OPTIONS

John M. Herre, MD, FACC, FACP

Director, Advanced Heart Failure ProgramSentara Helathcare

Professor of Medicine Eastern Virginia Medical School

Page 2: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

PATIENT 1

• Onset heart failure at age 70• Normal coronary arteries• Optimal oral medical management• Resynchronization ICD• Recurrent hospitalizations for heart failure and

VT• EF < 10 %• LVEDD 7.5 cm

2

Page 3: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

PATIENT 1• Age 72• Improvement with milrinone

– Creatinine 0.9– Albumin 3.7– INR 1.2– RA 12 (2-5)– PCW 22 (5-12)– RVSWI 832 (>600)

• Recurrence of symptoms off milrinone

3

Page 4: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

WHAT DO YOU RECOMMEND

1. Hospice2. Bridge to hospice with milrinone3. Long term home milrinone4. Heart transplant5. Mechanical circulatory support

4

Page 5: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

OUTCOMES OF CONTINUOUS HOME MILRINONE THERAPY

Group 1 yr surv Baseline NYHA 6 m NYHA(if alive)

Bridge to TX/VAD 83.3% 3.89 2

Weaning strategy 73.4 3.92 2

Palliative care 11.1 3.76 3

5

Muthsusamy, JHLT 2012, 31:S14

Page 6: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

Figure 12

Source: The Journal of Heart and Lung Transplantation 2012; 31:1052-1064 (DOI:10.1016/j.healun.2012.08.002 )

TRANSPLANT SURVIVAL BY AGE

Page 7: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

~240 MillionUS Population ≥ 20 years old

6.24 MillionHF = 2.6% of the population

3.12 Million Systolic HF = 50% of HF population

124,800 Adv. Stage C / NYHA IIIB

Advanced Stage C = 3-4%

156,000 Stage D / NYHA IV = 0.5-5%

70,200 Potential candidates for transplant

THE PROBLEM

2000 heart transplants per year2000 heart transplants per year

Courtesy John O’Connell, MD

Page 8: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

DURABLE MECHANICAL CIRCULATORY SUPPORT

8

Page 9: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

ASSESSING THE BENEFIT

HEARTMATE II RISK SCORE

9

0.0274 x age – 0.723 x albumin + 0.74 x creatinine + 1.136 x INR for centers with > 15 implants per year

1.978 – 2.6751 + 0.66 + 1.3632 = 1.349

Cowger, JACC, 2013

Page 10: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

HEARTMATE II RISK SCORE

10

Cowger, JACC, 2013

Page 11: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

PATIENT 1

11

Page 12: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

PATIENT 2• 72 years old male• Diabetic• CAD• Prior CABG and mitral valve repair• Recurrent hospitalizations for heart failure• 30 lb weight loss• Creatinine 2.9• Albumin 3.0• INR 1.5

12

Page 13: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

WHAT DO YOU RECOMMEND

13

1. Hospice

2. Bridge to hospice with milrinone

3. Long term home milrinone

4. Heart transplant

5. Mechanical circulatory support

Page 14: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

SURVIVAL IN HEART FAILURE

14

0

0.5

1

1.5

2

2.5

3

No CKD With CKD Age 75-85 Age > 85

1 hosp

2 hosp

3 hosp

4 hosp

3

2.5

2

1.5

1

0.5

0

No CKD CKD Age 75-85 Age > 85

1

2

3

4

HospitalizationsMedian

Survival

(years)

Setoguchi, Am Heart J 2007

Page 15: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

PATIENT 2HEARTMATE II RISK SCORE

15

0.0274 x age – 0.723 x albumin + 0.74 x creatinine + 1.136 x INR for centers with > 15 implants per year

1.9728 – 2.169 + 2.146 + 1.704 = 3.6538

Page 16: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

HEARTMATE II RISK SCORE

16

Cowger, JACC 2013

Page 17: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

17

Profile Description Time to MCS

1 “Crashing and burning” - critical cardiogenic shock. Within hours

2“Progressive decline” – inotrope dependence with continuing

deterioration.Within a few days

3

“Stable but inotrope dependent” - describes clinical stability on mild-

moderate doses of intravenous inotropes. (Patients stable on temporary

circulatory support without inotropes are within this profile).

Within a few weeks

4“Recurrent advanced heart failure” - “recurrent” rather than

“refractory” decompensation.

Within weeks

to months

5“Exertion intolerant” - describes patients who are comfortable at rest

but are exercise intolerant.Variable

6

“Exertion limited” – a patient who is able to do some mild activity but

fatigue results within a few minutes or any meaningful physical

exertion.

Variable

7

“Advanced ” - describes patients who are clinically stable with a

reasonable level of comfortable activity, despite history of previous

decompensation that is not recent.

Not a candidate

for MCS

Page 18: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

SURVIVAL TO DISCHARGE

18

70.4

93.5 95.8

0

20

40

60

80

100

% s

urv

ival

Group 1(n=27)

Group 2(n=48)

Group 3 (n=24)

Boyle JHLT 2011

Page 19: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

LENGTH OF STAY

19

4441

17

0

10

20

30

40

50

60D

ay

s

Group 1(n=27)

Group 2(n=48)

Group 3(n=24)

Boyle JHLT 2011

Page 20: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

RISK FACTORS FOR EARLY DEATHRisk Factor Hazard Ratio P-value

Prior stroke 1.74 0.005

Prior CABG 1.84 <0.0001

INTERMACS 1 2.87 0.0001

INTERMACS 2 1.84 0.01

BiVAD 3.27 <0.0001

Prior valve surgery 1.81 0.0007

20

Kirklin, JHLT 2012, 31:117

Page 21: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

OTHER CONSIDERATIONS• Support system• Understand the risks• Understand the lifestyle• Desire to proceed• Ability to interpret and act on alarms• Understand options including palliative care

21

Page 22: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

22

PATIENT 3• 30 years old • ODU graduate• Program Development Director for

Muscular Dystrophy Association• Bought a condo • Acquired a small dog

• Progressive cough and dyspnea for 6 weeks

• Couldn’t carry dog up the steps• Diagnosis – bronchitis, reflux• 2 courses of outpatient antibiotics • Sent to ER by PCP for pneumonia

Page 23: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

23

1. Bilateral lower lobe air space opacities with effusions, right greater than left. Findings may be related to multifocal pneumonia or aspiration. Recommend radiographic follow-up to clearance.2. Mildly enlarged cardiac silhouette

Page 24: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

HOSPITALIST ASSESSMENT

24

Assessment:

Patient Active Hospital Problem List:

*Community Acquired Pneumonia (4/13/2010)

GERD (Gastroesophageal Reflux Disease) (4/13/2010)

Fatigue (4/13/2010)

Anxiety (4/13/2010)

Plan:

Treat for CAP. Prn nebulizer treatments.

Prn xanax for anxiety.

Continue home celexa.

Recommend repeat imaging during her hospital course.

Page 25: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

HOSPITAL COURSE• Respiratory arrest at 11 AM on 4/14• Cardiac arrest at 12 noon• Ejection fraction – 5-10% by echo• Persistent shock despite norepinephrine, dobutamine

• Creatinine 1.1• INR 1.58• Albumin 3.1• SGOT 1158• Lactate13.6

25

Page 26: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

WHAT DO YOU DO

1. Continue medical management2. Intraaortic balloon pump3. Temporary mechanical circulatory support4. Durable mechanical circulatory support5. Palliative care

26

Page 27: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

SHOCK II

27

Page 28: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

HOSPITAL COURSE

• Referred to Advanced Heart Failure Team at 2:30 PM• Briefly staibilized with intraaortic balloon pump• Progressive deterioration over next 30 min• To OR at 6:30PM for Acute Mechanical Circulatory

Support• Regained consciousness• End organ function recovered• Heart transplant 5/3/2010

28

Page 29: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

Saturday, May 22, 201019 days post transplant

Page 30: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

PATIENT 4• 28 years old male • Air Force veteran• 4-6 month history progressive deterioration• 3 week history of nausea, abdominal pain,

vomiting• Admitted to local hospital on 6/26/2012• INR 6.1• Creatinine 2.7• Albumin 1.9

30

Page 31: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

31

Page 32: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

PATIENT 4• Diagnosis: acute liver failure, acute renal

failure• Vitamin K, FFP• Considered urgent referral for liver

transplant• Cardiopulmonary arrest 6/27• EF 5-10%• Medical management• Transferred to SNGH 6/28/2012 for acute

mechanical circulatory support

32

Page 33: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

MANAGEMENT OPTIONS

1. Continue medical management2. Intraaortic balloon pump3. Temporary mechanical circulatory support4. Durable mechanical circulatory support5. Palliative care

33

Page 34: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

PATIENT 4• CentriMag temporary support

device• Restoration of circulation• Changout to durable device• Fungal device infection• Recovery of cardiac function• Device explant• Death from multiorgan failure

and heart failure• Family asks if earlier transfer

would have changed outcome

34

Page 35: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

WHAT’S THE DIFFERENCE• Same heart• Same age

• Case 4– Late presentation– Later referral– Irreversible end-organ damage

• Where do you draw the line?

35

Page 36: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

SUMMARY• Durable mechanical circulatory

– Referral before progressive renal or liver dysfunction– Referral before pressors are required– Referral before cardiac cachexia develops

• Acute, temporary mechanical circulatory support – Early recognition before irreversible end-organ damage– Early referral– Early initiation of mechanical support– Families of young, healthy patients who die are

litiginous

36

Page 37: 1 ADVANCED HEART FAILURE RECOGNIZING OPTIONS John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine

WHO HAS THE VAD?

37